Fluid (Atrophied T2 Lesion Volume) in Primary-Progressive Multiple Sclerosis: Results from the Phase III ORATORIO Study ----------------------- ---------------------------------------------- ------------------------------- Recently Diagnosed Early-Stage P15.099 RRMS: NEDA, ARR, Disability Progression, P15: MS Clinical Trials Serum Neurofilament and Safety: and Therapeutics 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study ---------------------------------------------- ------------------------------- Adherence and Persistence to Disease-modifying P15.228 Therapies for Multiple Sclerosis P15: MS Health Care and Their Impact on Clinical and System/Policy Based Economic Outcomes in a U.S. Claims Research Database ---------------------------------------------- ------------------------------- Safety of Ocrelizumab in Multiple P15.203 Sclerosis: Updated Analysis in P15: MS Therapeutics Patients with Relapsing and Primary MOA and Safety Progressive Multiple Sclerosis ----------------------- ---------------------------------------------- ------------------------------- Fenebrutinib The Safety of Fenebrutinib in a S25.005 (oral presentation) for Multiple Large Population of Patients with S25: MS and CNS Inflammatory Sclerosis Diverse Autoimmune Indications Disease: Emerging Therapeutics Supports Investigation in Multiple and Biomarkers Sclerosis (MS) Tuesday, April 20 at 4:40 pm ET ----------------------- ---------------------------------------------- ------------------------------- Fenebrutinib Demonstrates the Highest P15.091 Potency of Bruton Tyrosine Kinase P15: MS Clinical Trials Inhibitors (BTKis) in Phase 3 Clinical and Therapeutics Development for Multiple Sclerosis (MS) ----------------------- ---------------------------------------------- ------------------------------- ENSPRYNG (satralizumab) Satralizumab in Patients with Neuromyelitis P2.019 for Neuromyelitis Optica Spectrum Disorder and Concomitant P2: Autoimmune Neurology: Optica Spectrum Autoimmune Disease Advances in Neuromyelitis Disorder Optica Spectrum Disorder (NMOSD) ----------------------- ---------------------------------------------- ------------------------------- Neuromyelitis Disease Phenotype Correlates with P2.091 Optica Spectrum Treatment Change in NMOSD Patients P2: Autoimmune Neurology: Disorder of the CIRCLES Cohort Clinical Observations and Advances ----------------------- ---------------------------------------------- ------------------------------- Demographic and Relapse Correlates P2.013 of Treatment Change in NMOSD Patients: P2: Autoimmune Neurology: Analysis of the CIRCLES Study Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) ----------------------- ---------------------------------------------- ------------------------------- Relapse Profile Correlates with P2.012 Treatment Change in NMOSD Patients P2: Autoimmune Neurology: of the CIRCLES Cohort Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) ---------------------------------------------- ------------------------------- Correlates of Rituximab Discontinuation P2.014 in Patients with NMOSD: a CIRCLES P2: Autoimmune Neurology: Cohort Analysis Advances in Neuromyelitis Optica Spectrum Disorder (NMOSD) ----------------------- ---------------------------------------------- ------------------------------- Alzheimer's Linking Amyloid to Cognition in P1.052 Disease the Pathogenesis and Treatment P1: Aging and Dementia: of Alzheimer's Disease: Toward Biomarkers the Development of a "Quantitative A/T/N Model" ----------------------- ---------------------------------------------- ------------------------------- Gantenerumab Utilization of Home Nursing to P1.014 for Alzheimer's Mitigate the Impact of COVID-19 P1: Aging and Dementia: Disease on the Conduct of the Gantenerumab Clinical Trials GRADUATE Trials ----------------------- ---------------------------------------------- ------------------------------- Semorinemab A Disease Progression Model for P1.061 for Alzheimer's Alzheimer's Disease Predicts Longitudinal P1: Aging and Dementia: Disease Trajectory of CDR-SB Score Across Neuropsychology Different Stages of the Disease ----------------------- ---------------------------------------------- ------------------------------- Huntington's Burden of Illness among U.S. Medicare P14.043 Disease Beneficiaries with Late-onset Huntington's P14: Huntington's Disease Disease ----------------------- ---------------------------------------------- ------------------------------- Clinical Characteristics of Late-Onset P14.046 Huntington's Disease in North Americans P14: Huntington's Disease from the Enroll-HD Study ----------------------- ---------------------------------------------- ------------------------------- Clustering and Prediction of Disease P14.147 Progression Trajectories in Huntington's P14: Clinical Trials, Disease: An Analysis of the Enroll-HD Surveys, and Studies and REGISTRY Database Using a Machine in Movement Disorders Learning Approach ----------------------- ---------------------------------------------- ------------------------------- About EVRYSDI(TM) (risdiplam) EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat SMA by increasing production of the survival of motor neuron (SMN) protein. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. EVRYSDI is administered daily at home in liquid form by mouth or by feeding tube. The U.S. Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. At this time, EVRYSDI has been approved in 38 countries and submitted in a further 33 countries. About OCREVUS(R) (ocrelizumab) OCREVUS is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and PPMS, with dosing every six months. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions. With rapidly growing real-world experience and more than 200,000 people treated globally, OCREVUS is the first and only therapy approved for relapsing MS (RMS; including RRMS and active, or relapsing, secondary progressive
(MORE TO FOLLOW) Dow Jones Newswires
April 08, 2021 01:00 ET (05:00 GMT)